Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti PD-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05585814
What this trial is testing

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Shanghai Changzheng Hospital 30
Testing effectiveness (Phase 2)UnknownNCT03374293
What this trial is testing

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Shixiu Wu 21
Testing effectiveness (Phase 2)Study completedNCT04172506
What this trial is testing

Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

Who this might be right for
Solid TumorLung CancerHCC
Akeso 65
Testing effectiveness (Phase 2)Study completedNCT04068519
What this trial is testing

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Who this might be right for
Advanced Solid Tumors
BeiGene 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05518994
What this trial is testing

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Who this might be right for
Astrocytoma of Brain
Henan Provincial People's Hospital 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05479045
What this trial is testing

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer Stage IVOvarian Cancer Stage IIIOvarian Cancer Stage 3
Georgetown University 24
Large-scale testing (Phase 3)Looking for participantsNCT05125055
What this trial is testing

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Who this might be right for
Oral Squamous Cell CarcinomaNeoadjvant TherapyAnti-PD-1+1 more
Shanghai Jiao Tong University School of Medicine 80
Early research (Phase 1)UnknownNCT05370755
What this trial is testing

ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Who this might be right for
Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd. 22
Not applicableStudy completedNCT02840058
What this trial is testing

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

Who this might be right for
Cancer
Centre Hospitalier Universitaire de Besancon 295
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04825938
What this trial is testing

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Who this might be right for
Salivary Gland Malignant NeoplasmsSalivary Gland Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 15
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Early research (Phase 1)UnknownNCT04756934
What this trial is testing

HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Who this might be right for
Melanoma
Taizhou HoudeAoke Biomedical Co., Ltd. 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT05205330
What this trial is testing

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Who this might be right for
Refractory Metastatic Colorectal CancerSolid TumorMetastatic Microsatellite-stable Colorectal Cancer+3 more
Rottapharm Biotech 107
Testing effectiveness (Phase 2)UnknownNCT04635956
What this trial is testing

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Who this might be right for
ChemotherapyAnti-pd-1 AntibodyCervical Neuroendocrine Carcinoma+4 more
Lei Li 20
Large-scale testing (Phase 3)Looking for participantsNCT05582265
What this trial is testing

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Who this might be right for
Head and Neck Squamous Cell Carcinomas
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 537
Testing effectiveness (Phase 2)UnknownNCT06078657
What this trial is testing

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)PD-1 Inhibitors
The First Affiliated Hospital of Zhengzhou University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06573151
What this trial is testing

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

Who this might be right for
Lymphoma
Ruijin Hospital 28
Early research (Phase 1)Active Not RecruitingNCT03860272
What this trial is testing

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Who this might be right for
Advanced CancerAngiosarcomaColorectal Cancer Without Liver Metastases+5 more
Agenus Inc. 499
Testing effectiveness (Phase 2)Ended earlyNCT04999605
What this trial is testing

AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsRecurrent Ovarian CarcinomaRelapsed Ovarian Cancer+1 more
Akeso 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06873854
What this trial is testing

LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Who this might be right for
Advanced Solid Tumor
LaNova Medicines Limited 84
Next Page